Renaissance Technologies LLC Sells 64,800 Shares of Silence Therapeutics plc (NASDAQ:SLN)

Renaissance Technologies LLC cut its position in Silence Therapeutics plc (NASDAQ:SLN) by 62.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,100 shares of the company’s stock after selling 64,800 shares during the period. Renaissance Technologies LLC owned 0.13% of Silence Therapeutics worth $743,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Parkman Healthcare Partners LLC raised its position in shares of Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,063 shares during the period. SG Americas Securities LLC lifted its stake in shares of Silence Therapeutics by 10.5% in the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock valued at $151,000 after buying an additional 667 shares in the last quarter. Redmile Group LLC acquired a new position in shares of Silence Therapeutics during the first quarter valued at about $43,798,000. Janus Henderson Group PLC acquired a new position in shares of Silence Therapeutics during the first quarter valued at about $13,575,000. Finally, Lynx1 Capital Management LP increased its position in shares of Silence Therapeutics by 123.4% during the first quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock worth $11,375,000 after acquiring an additional 290,855 shares in the last quarter. 98.73% of the stock is owned by institutional investors and hedge funds.

Silence Therapeutics Trading Up 4.5 %

Shares of Silence Therapeutics stock opened at $19.45 on Wednesday. The business’s fifty day simple moving average is $18.01 and its 200 day simple moving average is $19.94. Silence Therapeutics plc has a 12 month low of $6.15 and a 12 month high of $27.72. The firm has a market capitalization of $582.10 million, a P/E ratio of -16.68 and a beta of 1.29.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10). Silence Therapeutics had a negative return on equity of 58.28% and a negative net margin of 222.44%. The company had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $11.28 million. Analysts predict that Silence Therapeutics plc will post -1.55 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on SLN. Chardan Capital reissued a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Friday, August 16th. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Friday, August 30th. Jefferies Financial Group started coverage on Silence Therapeutics in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price target for the company. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $49.00 target price on shares of Silence Therapeutics in a research note on Tuesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $57.20.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.